Word

T

Status

Dead

Status Code

604

Status Date

Saturday, July 9, 2022

Serial Number

90481364

Mark Type

3000

Filing Date

Friday, January 22, 2021

Published for Opposition

Tuesday, September 7, 2021

Abandoned Date

Saturday, July 9, 2022

Trademark Owner History

Adaptive Biotechnologies Corp. - Owner At Publication

Classifications

5 Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical assay kits comprised of diagnostic reagents and assays for medical use; Diagnostic kits comprised of medical immunosequencing-based diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical immunosequencing assay kits comprised of diagnostic reagents and assays for medical use; Medical immunosequencing-based assay kits comprised of medical grade reagents and sample plates for detecting cancer, autoimmune disease and infection

44 Providing medical diagnostic assays and diagnostic and prognostic testing for treatment purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals determine a patient's clinical diagnosis, the effectiveness of patient treatments, and to revise future treatments accordingly; medical services; consulting services in the field of medical diagnostic and prognostic testing; medical analysis services for diagnostic and prognostic testing and treatment purposes; providing medical diagnostic and prognostic testing services; providing medical immunosequencing-based testing for cancer, autoimmune disease and infection; consulting services in the field of medical immunosequencing-based testing; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services relating to the diagnosis and treatment of person

42 Providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; genome amplification; genotyping services for research or analysis purposes; laboratory research in the field of immune sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of immune sequencing; providing laboratory research services in the field of gene expression, namely, cancer biology; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; medical research; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; custom design and development of chemical reagents and biochemical assays; development of new technology for others in the field of immunotherapy; laboratory research in the field of immunotherapy, oncology, hematology, auto-immune disorders, and infectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services; medical laboratory immunosequencing-based services for analysis of biological samples

The mark consists of a capitalized letter "T" in stylized form.

Trademark Events

Jul 11, 2022

Abandonment Notice E-Mailed - Inter Partes Decision

Jul 9, 2022

Abandonment - After Inter Partes Decision

Jul 9, 2022

Opposition Terminated No. 999999

Jul 9, 2022

Opposition Sustained No. 999999

Nov 24, 2021

Opposition Instituted No. 999999

Sep 15, 2021

Extension Of Time To Oppose Received

Sep 7, 2021

Official Gazette Publication Confirmation E-Mailed

Sep 7, 2021

Published For Opposition

Aug 18, 2021

Notification Of Notice Of Publication E-Mailed

Aug 2, 2021

Approved For Pub - Principal Register

Jul 28, 2021

Examiner's Amendment Entered

Jul 28, 2021

Notification Of Examiners Amendment E-Mailed

Jul 28, 2021

Examiners Amendment E-Mailed

Jul 28, 2021

Examiners Amendment -Written

Jul 20, 2021

Assigned To Examiner

Apr 23, 2021

New Application Office Supplied Data Entered In Tram

Jan 26, 2021

New Application Entered In Tram